What is Sinco Pharmaceutical Holdings Operating Cash Flow per Share?
Sinco Pharmaceutical Holdings's operating cash flow per share for the
six
months ended in Dec. 2023 was HK$-0.04.
Sinco Pharmaceutical Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.19.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Sinco Pharmaceutical Holdings was 363.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 25.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Sinco Pharmaceutical Holdings's Operating Cash Flow per Share or its related term are showing as below:
HKSE:06833'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 7.7 Med: 30.4 Max: 55.2
Current: 25.6
During the past 10 years, Sinco Pharmaceutical Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 55.20% per year. The lowest was 7.70% per year. And the median was 30.40% per year.
HKSE:06833's 3-Year OCF Growth Rate is ranked better than 64.29% of 70
companies
in the Medical Distribution industry
Industry Median: 13.05
vs HKSE:06833: 25.60
Sinco Pharmaceutical Holdings Operating Cash Flow per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sinco Pharmaceutical Holdings Operating Cash Flow per Share Chart
Competitive Comparison of Sinco Pharmaceutical Holdings's Operating Cash Flow per Share
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings's Price-to-Operating-Cash-Flow Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's Price-to-Operating-Cash-Flow falls into.
Sinco Pharmaceutical Holdings Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Sinco Pharmaceutical Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinco Pharmaceutical Holdings Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Sinco Pharmaceutical Holdings (HKSE:06833) Business Description
Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06833 has been successfully added to your 